Verve Therapeutics Inc (NASDAQ:VERV): A High-Growth Momentum Stock Aligned with Minervini’s Trend Model

Verve Therapeutics Inc (NASDAQ:VERV): A Strong Growth Option Matching Minervini’s Trend Model

Mark Minervini’s trend-based strategy looks for stocks with solid technical and fundamental traits, confirming they are in a clear uptrend with improving growth. The method uses technical checks, like moving averages, relative strength, and price trends, along with fundamental filters to find stocks with high earnings and revenue growth. Verve Therapeutics Inc (VERV) has been identified by a "High Growth Momentum + Trend Template" screen, indicating it fits both Minervini’s technical standards and high-growth investment ideas.

Why VERV Matches the Minervini Trend Model

The Minervini Trend Model needs stocks to meet several technical conditions to confirm a strong uptrend. VERV meets these key points:

• Price Above Important Moving Averages:

  • The stock is above its 50-day ($8.21), 150-day ($6.71), and 200-day ($6.45) moving averages, showing steady upward movement.
  • The 50-day MA is higher than the 150-day and 200-day MAs, a positive sign confirming alignment across timeframes.
  • Both the 150-day and 200-day MAs are moving up, supporting long-term strength.

• Strong Price Action:

  • VERV is close to its 52-week high ($11.40), a sign of leadership and momentum.
  • The stock has risen 93% in the last three months and 50% over the past year, showing consistent upward progress.

• High Relative Strength:

  • With a relative strength (RS) score of 95.29, VERV beats 95% of all stocks in the market and 92% of its biotechnology peers, a trait of top-performing stocks.

These factors match Minervini’s view that the best stocks are often near new highs, show strong relative strength, and have rising moving averages.

High Growth Momentum Fundamentals

Beyond technicals, VERV shows improving growth metrics that attract growth-focused investors:

• Rapid Revenue Growth:

  • Quarterly revenue growth (YoY) is 479%, with prior quarters showing 154%, 120%, and 220% growth.
  • Full-year revenue growth (TTM) is 271%, showing fast expansion.

• Earnings Improvement:

  • Despite negative EPS (common in biotech growth stages), quarterly EPS growth (YoY) is 40.7%, with prior quarters at 15.9%, 18.1%, and 32.2% growth.
  • Analysts have increased next-year EPS estimates by 8.6% in the last three months, reflecting confidence.

• Strong Institutional Support:

  • Recent volume spikes suggest buying interest, with the 5-day average volume (8.29M shares) above the 50-day average (5.52M shares).

These fundamentals meet the "High Growth Momentum" screen’s needs, as VERV shows the kind of improving growth that often leads to further price gains.

Technical Setup and Trade Ideas

ChartMill’s technical report gives VERV a rating of 8/10, noting:

• A bull flag pattern, hinting at a possible continuation of the uptrend.
• Key support at $10.90–$11.11, with resistance near $11.31–$11.39. A break above resistance could signal more upside.
• A recent pocket pivot (a bullish signal with volume) adds to the positive outlook.

For a full review, see the detailed technical analysis report.

Conclusion

Verve Therapeutics is a strong option for growth-focused investors using Minervini’s approach. Its solid technical position, combined with fast revenue growth and institutional interest, makes it a high-potential choice. While biotech stocks are volatile, VERV’s fit with both trend-based and high-growth criteria makes it worth further study.

Find More High-Growth Trend Options
For other stocks meeting the Minervini Trend Model and High Growth Momentum criteria, check the screen here.

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider risk management strategies before trading.